John J. Nicols net worth and biography

John Nicols Biography and Net Worth

CEO of Codexis
John J. Nicols serves as President, Chief Executive Officer, Director of Codexis, Inc. Mr. Nicols brings to our board of directors his knowledge of Codexis as its President and Chief Executive Officer and his extensive prior management experience in the chemicals industry. Prior to that time, Mr. Nicols served in various capacities at Albemarle Corporation, a public company focused on the development, manufacture and marketing of highly engineered specialty chemicals, since he joined that company in 1990. Mr. Nicols most recently served as its Senior Vice President, Strategic Development and Catalysts, from March 2012 to June 2012. Mr. Nicols previously served as its Vice President, Catalysts from January 2007 to February 2012, its Vice President, Fine Chemistry from June 2002 to December 2006, its Division Vice President, Global Flame Retardants business from February 1999 through June 2002 and its Asia Pacific Business Director for the Bromine Chemicals business, based in Tokyo, Japan, from 1995 to 1998. Prior to his time with Albemarle Corporation, Mr. Nicols worked for three years in manufacturing and research and development for Hercules, Inc. Mr. Nicols has served on the board of directors of California Life Sciences Association (formerly BayBio), a non-profit organization, since January 2014. In addition, Mr. Nicols has served on the board of directors of Solve ME/CFS Initiative, a non-profit organization, since January 2015, and currently serves as chairperson and on the executive and nominating committees of that organization. Mr. Nicols received a B.S. in Chemical Engineering from the Polytechnic Institute of New York University and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.

What is John J. Nicols' net worth?

The estimated net worth of John J. Nicols is at least $3.17 million as of March 15th, 2023. Mr. Nicols owns 783,965 shares of Codexis stock worth more than $3,167,219 as of March 21st. This net worth estimate does not reflect any other investments that Mr. Nicols may own. Learn More about John J. Nicols' net worth.

What is John J. Nicols' salary?

As the CEO of Codexis, Inc., Mr. Nicols earned a total compensation package of $3,438,179.00 in 2021. Mr. Nicols earned a salary of $696,562.00, options awards of $2,109,577.00, non-equity compensation of $619,000.00, and other compensation of $13,040.00. Learn More on John J. Nicols' salary.

How do I contact John J. Nicols?

The corporate mailing address for Mr. Nicols and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected] Learn More on John J. Nicols' contact information.

Has John J. Nicols been buying or selling shares of Codexis?

During the last ninety days, John J. Nicols has sold $547,852.76 in shares of Codexis stock. Most recently, John J. Nicols sold 35,714 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $4.09, for a transaction totalling $146,070.26. Following the completion of the sale, the director now directly owns 783,965 shares of the company's stock, valued at $3,206,416.85. Learn More on John J. Nicols' trading history.

Who are Codexis' active insiders?

Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.

Are insiders buying or selling shares of Codexis?

In the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 410,757 shares worth more than $2,709,271.10. The most recent insider tranaction occured on March, 15th when Director John J Nicols sold 35,714 shares worth more than $146,070.26. Insiders at Codexis own 7.0% of the company. Learn More about insider trades at Codexis.

Information on this page was last updated on 3/15/2023.

John J. Nicols Insider Trading History at Codexis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2023Sell35,714$4.09$146,070.26783,965View SEC Filing Icon  
2/24/2023Sell35,714$4.83$172,498.62783,965View SEC Filing Icon  
1/24/2023Sell35,714$6.42$229,283.88823,750View SEC Filing Icon  
12/12/2022Sell35,714$5.68$202,855.52863,535View SEC Filing Icon  
12/9/2022Sell39,785$5.66$225,183.10863,535View SEC Filing Icon  
10/28/2022Sell35,716$5.53$197,509.48943,106View SEC Filing Icon  
10/6/2022Sell35,716$5.99$213,938.84982,892View SEC Filing Icon  
8/15/2022Sell39,000$8.78$342,420.001,022,679View SEC Filing Icon  
8/12/2022Sell38,500$8.62$331,870.001,022,679View SEC Filing Icon  
5/12/2022Sell38,500$10.31$396,935.001,022,679View SEC Filing Icon  
3/10/2022Sell38,500$18.93$728,805.00View SEC Filing Icon  
11/10/2021Sell35,000$40.29$1,410,150.00View SEC Filing Icon  
8/20/2019Buy10,000$13.30$133,000.001,082,679View SEC Filing Icon  
3/19/2019Sell55,072$20.83$1,147,149.761,087,751View SEC Filing Icon  
12/7/2018Sell43,812$21.78$954,225.361,112,679View SEC Filing Icon  
9/28/2018Sell80,000$17.57$1,405,600.001,112,679View SEC Filing Icon  
8/15/2018Sell14,259$15.14$215,881.261,084,538View SEC Filing Icon  
6/11/2018Sell9,007$15.18$136,726.261,079,886View SEC Filing Icon  
6/8/2018Sell7,207$15.35$110,627.451,079,886View SEC Filing Icon  
3/23/2018Sell22,465$11.57$259,920.051,078,990View SEC Filing Icon  
3/8/2013Buy27,000$2.42$65,340.00View SEC Filing Icon  
3/7/2013Buy54,000$2.22$119,880.00View SEC Filing Icon  
See Full Table

John J. Nicols Buying and Selling Activity at Codexis

This chart shows John J Nicols's buying and selling at Codexis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codexis Company Overview

Codexis logo
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Read More

Today's Range

Now: $4.04
Low: $3.93
High: $4.07

50 Day Range

MA: $5.52
Low: $3.86
High: $6.76

2 Week Range

Now: $4.04
Low: $3.79
High: $22.22


420,574 shs

Average Volume

656,464 shs

Market Capitalization

$266.44 million

P/E Ratio


Dividend Yield